PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
R&D reduction while TRVN shows 23.10% growth. Joel Greenblatt would examine competitive risk.
108.24%
G&A growth above 1.5x TRVN's 7.49%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Other expenses reduction while TRVN shows 0.00% growth. Joel Greenblatt would examine efficiency.
-3.86%
Operating expenses reduction while TRVN shows 20.95% growth. Joel Greenblatt would examine advantage.
-3.86%
Total costs reduction while TRVN shows 20.95% growth. Joel Greenblatt would examine advantage.
-100.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
-1.12%
D&A reduction while TRVN shows 7.36% growth. Joel Greenblatt would examine efficiency.
-1.49%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
3.86%
Operating income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-73.89%
Other expenses reduction while TRVN shows 2.45% growth. Joel Greenblatt would examine advantage.
-1.47%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing tax expense. Martin Whitman would check patterns.
-1.47%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
12.77%
EPS growth while TRVN declines. John Neff would investigate advantages.
13.49%
Diluted EPS growth while TRVN declines. John Neff would investigate advantages.
16.41%
Share count reduction below 50% of TRVN's 3.15%. Michael Burry would check for concerns.
17.29%
Diluted share reduction below 50% of TRVN's 3.15%. Michael Burry would check for concerns.